항정신병 약물 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of antipsychotic drugs Market

The global antipsychotic drugs market was valued at USD 18.51 billion in 2025 and is projected to grow to USD 19.71 billion in 2026, ultimately reaching USD 27.48 billion by 2034, exhibiting a CAGR of 5.24% during the forecast period. North America dominated the global market in 2025 with a share of 52.32%, driven by the high prevalence of psychiatric illnesses, strong presence of leading biopharmaceutical companies, and the adoption of technologically advanced antipsychotic medications.

Market Overview

Psychiatric illnesses, including schizophrenia, bipolar disorder, and depression, are the primary drivers of the antipsychotic drugs market. Psychosis, a key symptom of these illnesses, affects patients' perception of reality and information processing. The rising prevalence of schizophrenia and bipolar disorder has fueled the demand for effective antipsychotic medications globally. Moreover, the adoption of newer drug formulations, particularly long-acting injectables (LAIs), has significantly enhanced treatment adherence and outcomes.

COVID-19 also influenced the market positively by accelerating the transition toward telemedicine for psychiatric care, which increased medication adoption. Market growth is expected to stabilize between 2024 and 2032 due to improved healthcare systems and treatment accessibility.

Market Segmentation

By Disease:

• Schizophrenia: The fastest-growing segment due to its global prevalence and the launch of multiple innovative products.
• Bipolar Disorder: Second-largest segment, with drugs helping stabilize symptoms. Lifetime prevalence is around 1%, with a one-year prevalence of 0.5%.
• Unipolar Depression: Third-largest segment, with medications like Rexulti providing symptomatic relief.
• Dementia: Smaller segment due to the FDA black box warning limiting antipsychotic use in elderly patients.

By Therapeutic Class:

• Second Generation Antipsychotics dominated with a 76.12% share in 2026, thanks to a superior safety profile and drugs like SEROQUEL XR, ZYPREXA, VRAYLAR, INVEGA HAFYERA, and Rexulti.
• Third Generation is expected to exhibit the highest CAGR, supported by new product launches and technological advancements.
• First Generation shows the lowest growth due to higher risk of neurological side effects.

By Drug:

• Aripiprazole leads in growth due to third-generation adoption and significant product approvals, including the FDA-approved 2-month LAI for schizophrenia and bipolar I disorder (2022).
• Paliperidone Palmitate holds the second-largest market share, with INVEGA HAFYERA being the first twice-yearly injectable approved for schizophrenia in adults (2021).
• Other drugs contribute to market dominance due to the variety of available options.

By Distribution Channel:

• Hospital pharmacies account for the largest market share (43.54% in 2026) as most antipsychotics require prescription and monitoring.
• Online pharmacies are expected to grow the fastest due to patient convenience.
• Drug stores & retail pharmacies remain significant for prescription refills and oral medications.

Regional Insights

• North America: Market size USD 9.69 billion in 2025, projected USD 10.33 billion in 2026, dominating due to prevalence, R&D, and technological adoption.
• Europe: USD 3.91 billion in 2025, USD 4.13 billion in 2026; strong government spending and awareness boost market growth.
• Asia Pacific: USD 3.73 billion in 2025, USD 4.03 billion in 2026; fastest-growing region due to emerging countries like China and India.
• Latin America: USD 0.74 billion in 2025, USD 0.77 billion in 2026; growth driven by increased awareness and healthcare expenditure.
• Middle East & Africa: USD 0.45 billion in 2025, USD 0.46 billion in 2026; limited share but growing due to improved healthcare systems.

Market Trends and Growth Drivers

1. Adoption of Long-Acting Injectables (LAIs): LAIs improve adherence and reduce relapse risks. For example, Paliperidone LAIs require administration only four times a year.

2. R&D Initiatives: Companies like Karuna Therapeutics are developing innovative drugs like KarXT for schizophrenia and psychosis in Alzheimer's.

3. Rising Prevalence of Mental Disorders: WHO predicts mental disorders will cost the global economy USD 6 trillion by 2030, intensifying demand.

Restraining Factors

Adverse effects, including weight gain, sedation, digestive issues, and tardive dyskinesia, can lead to non-adherence. Black box warnings, such as for dementia patients, also limit market adoption.

Key Players

• Janssen Global Services LLC - Invega Sustenna, Risperdal Consta
• Otsuka Pharmaceutical Co., Ltd. - Abilify Maintena, Rexulti
• Eli Lilly and Company - Various antipsychotics
• Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Bristol-Myers Squibb, Dr. Reddy's Laboratories, Sumitomo Dainippon Pharma Co., Alkermes plc

Industry Developments

• January 2024: Teva completes Phase 3 trial for once-monthly olanzapine LAI.
• April 2023: FDA approves UZEDY (risperidone LAI) by Teva and MedinCell.
• January 2022: FDA approves REXULTI for adolescents (13-17 years) with schizophrenia.

Conclusion

The global antipsychotic drugs market is poised for steady growth from 2025 to 2034, driven by rising mental health disorders, innovative LAIs, and active R&D pipelines. North America will continue to lead, while Asia Pacific emerges as the fastest-growing market, supported by awareness programs and increasing patient adoption of modern therapies.

Segmentation By Disease

• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Others

By Drug

• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• Paliperidone Palmitate
• Others

By Therapeutic Class

• First Generation
• Second Generation
• Third Generation

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country)
  • U.S. (By Disease)
  • Canada (By Disease)
• Europe (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
  • Germany (By Disease)
  • U.K. (By Disease)
  • France (By Disease)
  • Italy (By Disease)
  • Spain (By Disease)
  • Scandinavia (By Disease)
  • Rest of Europe (By Disease)
• Asia Pacific (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
  • China (By Disease)
  • Japan (By Disease)
  • India (By Disease)
  • Australia (By Disease)
  • Southeast Asia (By Disease)
  • Rest of Asia Pacific (By Disease)
• Latin America (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
  • Brazil (By Disease)
  • Mexico (By Disease)
  • Rest of Latin America (By Disease)
• Middle East & Africa (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
  • GCC (By Disease)
  • South Africa (By Disease)
  • Rest of Middle East & Africa (By Disease)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Psychiatric Disorders, By Key Countries/Regions
• 4.2. Analysis of the Cost and Burden of Mental Health Disorders
• 4.3. Overview of Current Advances in R&D for Antipsychotic Drugs
• 4.4. Pipeline Analysis, Key Players
• 4.5. Analysis: First Generation Antipsychotics vs. Third Generation Antipsychotics
• 4.6. Key Industry Developments, Mergers, Acquisitions, Etc.
• 4.7. New Product Launches
• 4.8. Impact of COVID-19 on Antipsychotic Drugs Market

5. Global Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast- By Disease
  • 5.1.1. Schizophrenia
  • 5.1.2. Bipolar Disorder
  • 5.1.3. Unipolar Depression
  • 5.1.4. Dementia
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast- By Drug
  • 5.2.1. Risperidone
  • 5.2.2. Quetiapine
  • 5.2.3. Olanzapine
  • 5.2.4. Aripiprazole
  • 5.2.5. Brexpiprazole
  • 5.2.6. Paliperidone Palmitate
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Therapeutic Class
  • 5.3.1. First Generation
  • 5.3.2. Second Generation
  • 5.3.3. Third Generation
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Drug Stores & Retail Pharmacies
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast- By Disease
  • 6.1.1. Schizophrenia
  • 6.1.2. Bipolar Disorder
  • 6.1.3. Unipolar Depression
  • 6.1.4. Dementia
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast- By Drug
  • 6.2.1. Risperidone
  • 6.2.2. Quetiapine
  • 6.2.3. Olanzapine
  • 6.2.4. Aripiprazole
  • 6.2.5. Brexpiprazole
  • 6.2.6. Paliperidone Palmitate
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Therapeutic Class
  • 6.3.1. First Generation
  • 6.3.2. Second Generation
  • 6.3.3. Third Generation
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Drug Stores & Retail Pharmacies
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
    • 6.5.1.1. By Disease
  • 6.5.2. Canada
    • 6.5.2.1. By Disease

7. Europe Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast- By Disease
  • 7.1.1. Schizophrenia
  • 7.1.2. Bipolar Disorder
  • 7.1.3. Unipolar Depression
  • 7.1.4. Dementia
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast- By Drug
  • 7.2.1. Risperidone
  • 7.2.2. Quetiapine
  • 7.2.3. Olanzapine
  • 7.2.4. Aripiprazole
  • 7.2.5. Brexpiprazole
  • 7.2.6. Paliperidone Palmitate
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Therapeutic Class
  • 7.3.1. First Generation
  • 7.3.2. Second Generation
  • 7.3.3. Third Generation
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Drug Stores & Retail Pharmacies
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
    • 7.5.1.1. By Disease
  • 7.5.2. U.K.
    • 7.5.2.1. By Disease
  • 7.5.3. France
    • 7.5.3.1. By Disease
  • 7.5.4. Italy
    • 7.5.4.1. By Disease
  • 7.5.5. Spain
    • 7.5.5.1. By Disease
  • 7.5.6. Scandinavia
    • 7.5.6.1. By Disease
  • 7.5.7. Rest of Europe
    • 7.5.7.1. By Disease

8. Asia Pacific Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast- By Disease
  • 8.1.1. Schizophrenia
  • 8.1.2. Bipolar Disorder
  • 8.1.3. Unipolar Depression
  • 8.1.4. Dementia
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast- By Drug
  • 8.2.1. Risperidone
  • 8.2.2. Quetiapine
  • 8.2.3. Olanzapine
  • 8.2.4. Aripiprazole
  • 8.2.5. Brexpiprazole
  • 8.2.6. Paliperidone Palmitate
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Therapeutic Class
  • 8.3.1. First Generation
  • 8.3.2. Second Generation
  • 8.3.3. Third Generation
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Drug Stores & Retail Pharmacies
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
    • 8.5.1.1. By Disease
  • 8.5.2. India
    • 8.5.2.1. By Disease
  • 8.5.3. Japan
    • 8.5.3.1. By Disease
  • 8.5.4. Australia
    • 8.5.4.1. By Disease
  • 8.5.5. Southeast Asia
    • 8.5.5.1. By Disease
  • 8.5.6. Rest of Asia Pacific
    • 8.5.6.1. By Disease

9. Latin America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast- By Disease
  • 9.1.1. Schizophrenia
  • 9.1.2. Bipolar Disorder
  • 9.1.3. Unipolar Depression
  • 9.1.4. Dementia
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast- By Drug
  • 9.2.1. Risperidone
  • 9.2.2. Quetiapine
  • 9.2.3. Olanzapine
  • 9.2.4. Aripiprazole
  • 9.2.5. Brexpiprazole
  • 9.2.6. Paliperidone Palmitate
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Therapeutic Class
  • 9.3.1. First Generation
  • 9.3.2. Second Generation
  • 9.3.3. Third Generation
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Drug Stores & Retail Pharmacies
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
    • 9.5.1.1. By Disease
  • 9.5.2. Mexico
    • 9.5.2.1. By Disease
  • 9.5.3. Rest of Latin America
    • 9.5.3.1. By Disease

10. Middle East & Africa Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast- By Disease
  • 10.1.1. Schizophrenia
  • 10.1.2. Bipolar Disorder
  • 10.1.3. Unipolar Depression
  • 10.1.4. Dementia
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast- By Drug
  • 10.2.1. Risperidone
  • 10.2.2. Quetiapine
  • 10.2.3. Olanzapine
  • 10.2.4. Aripiprazole
  • 10.2.5. Brexpiprazole
  • 10.2.6. Paliperidone Palmitate
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Therapeutic Class
  • 10.3.1. First Generation
  • 10.3.2. Second Generation
  • 10.3.3. Third Generation
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Drug Stores & Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
    • 10.5.1.1. By Disease
  • 10.5.2. South Africa
    • 10.5.2.1. By Disease
  • 10.5.3. Rest of Middle East & Africa
    • 10.5.3.1. By Disease

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2026)
• 11.2. Company Profiles
  • 11.2.1. Otsuka Pharmaceutical Co., Ltd.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Teva Pharmaceutical Industries Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Dr. Reddy's Laboratories Ltd.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. H. Lundbeck A/S
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. ALLERGAN (AbbVie, Inc.)
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Eli Lilly and Company
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Alkermes plc
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Bristol-Myers Squibb Company
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Sumitomo Dainippon Pharma Co., Ltd.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)